Company intelligence / Profile preview
siRNAgen Therapeutics
Cambridge, Massachusetts, USsirnagen.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Developing RNAi therapies for chronic inflammatory and CNS conditions using proprietary SAMiRNA™ delivery technology. Lead candidate SRN-001 targets IPF with planned IND submission in late2022[5], though current pipeline shows Phase1 status[4].
- Therapeutic areas
- DermatologyPulmonologyNeurology
- Modalities
- RNAisiRNA
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Endless Frontier Labs at NYU Stern (2022 cohort)
Beyond the preview
Go deeper on siRNAgen Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNAgen Therapeutics.